Stocks · News reference
Filed: 2026-11-05 AccNo: 0001193125-26-449840 Size: 451 KB Item 1.01: Entry into a Material Definitive Agreement Item 1.02: Termination of a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Fate Therapeutics announced its financial results for the third quarter ended September 30, 2026, alongside updates on its clinical-stage autoimmune and oncology programs.
Fate Therapeutics, Inc. granted stock options and restricted stock units to newly hired non-executive employees as an inducement for employment.
Recent industry reporting highlights developments involving Artiva Biotherapeutics' NK cell therapy and Fate Therapeutics.
Fate Therapeutics shared updated preliminary clinical data for its FT819 cell therapy candidate during the American Society of Nephrology's Kidney Week 2026 conference.
Fate Therapeutics announced the appointment of Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to lead commercialization of its CAR T-cell therapies. Harrell brings over 25 years of commercial leadership experience, including expertise in launching first-in-class autoimmune therapies and establishing lupus treatments. He will oversee commercial strategy for FT819 (in Phase 2 RECLAIM-LN trial for lupus nephritis) and FT839 (Phase 1/2 trial for autoimmune indications), with focus on enabling outpatient administration in community settings.